Sponsor Professor Robert Power on his 65th birthday marathon, and support Burnet’s life-saving international programs. Donate today.
Providing direct-acting antiviral therapy (DAA) for hepatitis C in the community may improve hepatitis C treatment uptake and completion, therefore decreasing the morbidity and mortality associated with this infection.
Uptake of currently available hepatitis C treatment in Australia is low, with only two percent of those infected being treated each year. The reasons for this are multi-factorial, but a significant barrier is treatment accessibility.
With the advent of well-tolerated, short duration, interferon free DAA therapy there is an opportunity to increase access to treatment by providing care in the community.
This open-label, randomised, multi-centre study will examine the feasibility and cost of treating people infected with genotype 1 hepatitis C in a primary healthcare setting (PHCS) compared to a traditional, tertiary health care setting, using a highly effective DAA regimen.
Patients presenting to PHCS will be randomised to treatment for HCV in the PHCS versus the affiliated tertiary hospital hepatitis treatment service. Primary end points include treatment efficacy, retention in care and cost.
Exploring models of care for hepatitis C treatment will determine the most efficient and cost effective system to challenge the epidemic.
30 months from February 2015
For any general enquiries relating to this project, please contact: